US equities |
SNDK $1,150.89 ▲+0.00% MU $884.74 ▲+0.00% INTC $65.76 ▲+0.00% NVDA $204.64 ▲+0.00% SPCX $134.72 ▲+0.00% GOOGL $279.84 ▲+0.00% SKHY $149.21 ▲+0.00% TSLA $399.81 ▲+0.00%
FinancialContent

OptimizeRx Corporation - Common Stock (NQ:OPRX)

9.320 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OptimizeRx Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Preview: OptimizeRx's Earnings ↗
 
Via Benzinga
News headline image
A Closer Look at 5 Analyst Recommendations For OptimizeRx ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
OptimizeRx Reports Third Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Expert Ratings For OptimizeRx ↗
 
Via Benzinga
News headline image
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024 ↗
OPRX stock results show that OptimizeRx beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
OptimizeRx Reports Second Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
The Company’s AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results ↗
 
Via Benzinga
News headline image
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges 150 Points; Retail Sales Flat For April ↗
 
Via Benzinga
News headline image
OPRX Stock Earnings: OptimizeRx Beats EPS, Beats Revenue for Q1 2024 ↗
OPRX stock results show that OptimizeRx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
OptimizeRx Reports First Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >